| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Theodosios D Filippatos, Thalia V Panagiotopoulou, Moses S Elisa. Adverse Effects of GLP-1 Receptor Agonists. The review of diabetic studies : RDS. vol 11. issue 3-4. 2016-05-27. PMID:26177483. |
one benefit of glp-1 receptor agonists is that they do not cause hypoglycemia when combined with metformin or thiazolidinediones, but the dose of concomitant sulphonylurea or insulin may have to be decreased to reduce the risk of hypoglycemic episodes. |
2016-05-27 |
2023-08-13 |
Not clear |
| Yun-cheng Zhen. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. Yao xue xue bao = Acta pharmaceutica Sinica. vol 50. issue 12. 2016-05-26. PMID:27169293. |
the fusion protein stimulated the ins-1 cells secretion of insulin, glp-1, exendin-4 and fusion protein in cd1 mice pharmacokinetic experiments, as well as glp-1, exendin-4 and fusion protein did anti-diabetic effect on streptozotocin induced mice. |
2016-05-26 |
2023-08-13 |
mouse |
| Sara T Hjuler, Kim V Andreassen, Sofie Gydesen, Morten A Karsdal, Kim Henrikse. KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration. European journal of pharmacology. vol 762. 2016-05-24. PMID:26027795. |
furthermore, kbp-042 was found to reduce incretins glp-1 and gip and considerably, improve gastric emptying, and to alleviate leptin resistance, as well as insulin resistance. |
2016-05-24 |
2023-08-13 |
rat |
| Ana Ines Cases, Takao Ohtsuka, Hideyo Kimura, Biao Zheng, Koji Shindo, Yoshinao Oda, Kazuhiro Mizumoto, Masafumi Nakamura, Masao Tanak. Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Oncology reports. vol 34. issue 4. 2016-05-20. PMID:26238361. |
glucagon-like peptide 1 (glp-1) induces insulin secretion and proliferation of pancreatic β-cells, and inhibits their apoptosis through the glp-1 receptor (glp-1r), thus providing a foundation for using glp-1-based therapies for the treatment of type 2 diabetes. |
2016-05-20 |
2023-08-13 |
Not clear |
| Charles F Shaefer, John Anderso. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. Postgraduate medicine. vol 128. issue 1. 2016-05-20. PMID:26548422. |
emerging strategies such as long-acting basal insulin analogs and short-acting glp-1 ras are particularly appealing to address this challenge. |
2016-05-20 |
2023-08-13 |
Not clear |
| Simona S Ghanem, Garrett Heinrich, Sumona G Lester, Verena Pfeiffer, Sumit Bhattacharya, Payal R Patel, Anthony M DeAngelis, Tong Dai, Sadeesh K Ramakrishnan, Zachary N Smiley, Dae Y Jung, Yongjin Lee, Tadahiro Kitamura, Suleyman Ergun, Rohit N Kulkarni, Jason K Kim, David R Giovannucci, Sonia M Najja. Increased Glucose-induced Secretion of Glucagon-like Peptide-1 in Mice Lacking the Carcinoembryonic Antigen-related Cell Adhesion Molecule 2 (CEACAM2). The Journal of biological chemistry. vol 291. issue 2. 2016-05-16. PMID:26586918. |
consistent with immunofluorescence analysis showing ceacam2 expression in distal intestinal villi, cc2(-/-) mice exhibited a higher release of oral glucose-mediated glp-1, an incretin that potentiates insulin secretion in response to glucose. |
2016-05-16 |
2023-08-13 |
mouse |
| Simona S Ghanem, Garrett Heinrich, Sumona G Lester, Verena Pfeiffer, Sumit Bhattacharya, Payal R Patel, Anthony M DeAngelis, Tong Dai, Sadeesh K Ramakrishnan, Zachary N Smiley, Dae Y Jung, Yongjin Lee, Tadahiro Kitamura, Suleyman Ergun, Rohit N Kulkarni, Jason K Kim, David R Giovannucci, Sonia M Najja. Increased Glucose-induced Secretion of Glucagon-like Peptide-1 in Mice Lacking the Carcinoembryonic Antigen-related Cell Adhesion Molecule 2 (CEACAM2). The Journal of biological chemistry. vol 291. issue 2. 2016-05-16. PMID:26586918. |
pretreating with exendin(9-39), a glp-1 receptor antagonist, suppressed the effect of ceacam2 deletion on glucose-induced insulin secretion. |
2016-05-16 |
2023-08-13 |
mouse |
| M Fishe. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective. Diabetes, obesity & metabolism. vol 17. issue 4. 2016-05-13. PMID:25155010. |
glucagon-like peptide 1 (glp-1) receptor agonists are a class of injected therapies that enhance the incretin effect, increasing insulin release from the pancreas and reducing glucagon production. |
2016-05-13 |
2023-08-13 |
Not clear |
| Hiroshi Nomoto, Hideaki Miyoshi, Tomoo Furumoto, Koji Oba, Hiroyuki Tsutsui, Arina Miyoshi, Takuma Kondo, Kenichi Tsuchida, Tatsuya Atsumi, Naoki Manda, Yoshio Kurihara, Shin Aok. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). PloS one. vol 10. issue 8. 2016-05-11. PMID:26284918. |
a comparison of the effects of the glp-1 analogue liraglutide and insulin glargine on endothelial function and metabolic parameters: a randomized, controlled trial sapporo athero-incretin study 2 (sais2). |
2016-05-11 |
2023-08-13 |
Not clear |
| Hiroshi Nomoto, Hideaki Miyoshi, Tomoo Furumoto, Koji Oba, Hiroyuki Tsutsui, Arina Miyoshi, Takuma Kondo, Kenichi Tsuchida, Tatsuya Atsumi, Naoki Manda, Yoshio Kurihara, Shin Aok. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). PloS one. vol 10. issue 8. 2016-05-11. PMID:26284918. |
therefore, we investigated the efficacy of the glp-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy. |
2016-05-11 |
2023-08-13 |
Not clear |
| Eugenia Lampropoulou, Anna Lymperopoulou, Aristidis Charoni. Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide. Metabolism: clinical and experimental. vol 65. issue 1. 2016-05-10. PMID:26683792. |
based on the above, we examined the possible involvement of erp46 in insulin production and the effect of the glp-1 analogue liraglutide on the expression of erp46 in vitro, in β-cells cultured under high glucose conditions and in vivo, in the mouse db/db diabetic model, where pronounced hyperglycemia is a key characteristic. |
2016-05-10 |
2023-08-13 |
mouse |
| C Weston, D Poyner, V Patel, S Dowell, G Ladd. Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast. British journal of pharmacology. vol 171. issue 15. 2016-05-09. PMID:24712679. |
the glucagon-like peptide 1 (glp-1) receptor performs an important role in glycaemic control, stimulating the release of insulin. |
2016-05-09 |
2023-08-13 |
Not clear |
| Joakim E Swedberg, Christina I Schroeder, Justin M Mitchell, Thomas Durek, David P Fairlie, David J Edmonds, David A Griffith, Roger B Ruggeri, David R Derksen, Paula M Loria, Spiros Liras, David A Price, David J Crai. Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European journal of medicinal chemistry. vol 103. 2016-05-09. PMID:26352676. |
recently, a number of smaller peptidomimetics containing 11-12 natural and unnatural amino acids have been identified that have similar insulin regulating profiles as glp-1. |
2016-05-09 |
2023-08-13 |
Not clear |
| R H A Becker, J Stechl, J Msihid, C Kapitz. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects. Diabetes, obesity & metabolism. vol 16. issue 9. 2016-05-06. PMID:24521245. |
glucagon-like peptide-1 (glp-1) receptor agonists improve blood glucose control by enhancing glucose-sensitive insulin release, delaying gastric emptying and reducing postprandial glucagon secretion. |
2016-05-06 |
2023-08-12 |
human |
| W Lane, S Weinrib, J Rappaport, C Hal. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes, obesity & metabolism. vol 16. issue 9. 2016-05-06. PMID:24589127. |
the addition of glucagon-like peptide-1 receptor agonists (glp-1 ras) to basal insulin therapy has been shown to reduce insulin requirement while reducing insulin-associated weight gain [1,2]. |
2016-05-06 |
2023-08-12 |
Not clear |
| W Lane, S Weinrib, J Rappaport, C Hal. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes, obesity & metabolism. vol 16. issue 9. 2016-05-06. PMID:24589127. |
the effect of glp-1 ra therapy added to intensive (basal/bolus) insulin therapy has not been studied in a prospective trial. |
2016-05-06 |
2023-08-12 |
Not clear |
| B Ahrén, J-F Gautier, R Berria, W Stager, R Aronson, C J Baile. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes, obesity & metabolism. vol 16. issue 9. 2016-05-06. PMID:24641271. |
this meta-analysis aimed to investigate the effects of the once-daily prandial glp-1 receptor agonist lixisenatide on postprandial plasma glucose (ppg), glucagon and insulin levels. |
2016-05-06 |
2023-08-12 |
Not clear |
| L J Miller, P M Sexton, M Dong, K G Harikuma. The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus. International journal of obesity supplements. vol 4. issue Suppl 1. 2016-05-06. PMID:27152167. |
glucagon-like peptide-1 (glp-1) is a gastrointestinal hormone secreted from l cells in the distal small intestine and proximal colon after a meal that acts as an incretin to augment the insulin response, while also inhibiting glucagon and slowing gastric emptying. |
2016-05-06 |
2023-08-13 |
Not clear |
| Manfredi Rizzo, Dragana Nikolic, Maciej Banach, Angelo Maria Patti, Giuseppe Montalto, Ali A Rizv. Incretin-based therapies, glucometabolic health and endovascular inflammation. Current pharmaceutical design. vol 20. issue 31. 2016-05-02. PMID:24320037. |
the ultimate effect of both types of agents is to augment glp-1 signaling, which results in enhanced glucose-dependent insulin secretion, inhibition of glucagon secretion and decreased appetite. |
2016-05-02 |
2023-08-12 |
Not clear |
| Simon Veedfald, Astrid Plamboeck, Carolyn F Deacon, Bolette Hartmann, Filip K Knop, Tina Vilsbøll, Jens J Hols. Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. American journal of physiology. Gastrointestinal and liver physiology. vol 310. issue 1. 2016-05-02. PMID:26492921. |
neither insulin, c-peptide, glucose-dependent insulinotropic polypeptide (gip), nor glucagon-like peptide-1 (glp-1) levels changed in response to msf or atropine. |
2016-05-02 |
2023-08-13 |
human |